GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (UKEX:PFE) » Definitions » Cyclically Adjusted Price-to-FCF

Pfizer (UKEX:PFE) Cyclically Adjusted Price-to-FCF : 8.98 (As of May. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pfizer Cyclically Adjusted Price-to-FCF?

As of today (2024-05-25), Pfizer's current share price is ₴1014.00. Pfizer's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was ₴112.91. Pfizer's Cyclically Adjusted Price-to-FCF for today is 8.98.

The historical rank and industry rank for Pfizer's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

UKEX:PFE' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 8.22   Med: 14.39   Max: 21.47
Current: 9.33

During the past years, Pfizer's highest Cyclically Adjusted Price-to-FCF was 21.47. The lowest was 8.22. And the median was 14.39.

UKEX:PFE's Cyclically Adjusted Price-to-FCF is ranked better than
89.78% of 313 companies
in the Drug Manufacturers industry
Industry Median: 33.08 vs UKEX:PFE: 9.33

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Pfizer's adjusted free cash flow per share data for the three months ended in Mar. 2024 was ₴2.716. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is ₴112.91 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Pfizer Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Pfizer's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Cyclically Adjusted Price-to-FCF Chart

Pfizer Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.05 15.25 20.86 15.98 9.33

Pfizer Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.64 11.60 10.61 9.33 8.97

Competitive Comparison of Pfizer's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Pfizer's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Pfizer's Cyclically Adjusted Price-to-FCF falls into.



Pfizer Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Pfizer's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=1014.00/112.91
=8.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Pfizer's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.716/131.7762*131.7762
=2.716

Current CPI (Mar. 2024) = 131.7762.

Pfizer Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 23.387 100.560 30.647
201409 24.432 100.428 32.058
201412 32.731 99.070 43.537
201503 2.765 99.621 3.657
201506 24.576 100.684 32.165
201509 30.150 100.392 39.576
201512 27.168 99.792 35.875
201603 9.706 100.470 12.730
201606 20.271 101.688 26.269
201609 28.064 101.861 36.306
201612 34.587 101.863 44.744
201703 8.068 102.862 10.336
201706 18.269 103.349 23.294
201709 28.484 104.136 36.044
201712 41.778 104.011 52.930
201803 10.359 105.290 12.965
201806 23.056 106.317 28.577
201809 31.458 106.507 38.922
201812 27.157 105.998 33.761
201903 7.530 107.251 9.252
201906 14.299 108.070 17.436
201909 27.309 108.329 33.220
201912 25.572 108.420 31.081
202003 19.171 108.902 23.198
202006 22.104 108.767 26.780
202009 11.267 109.815 13.520
202012 34.073 109.897 40.857
202103 28.210 111.754 33.264
202106 75.988 114.631 87.353
202109 71.506 115.734 81.417
202112 34.141 117.630 38.247
202203 41.066 121.301 44.612
202206 52.072 125.017 54.887
202209 35.990 125.227 37.872
202212 52.904 125.222 55.673
202303 0.511 127.348 0.529
202306 -14.891 128.729 -15.244
202309 18.789 129.860 19.066
202312 29.795 129.419 30.338
202403 2.716 131.776 2.716

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pfizer  (UKEX:PFE) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Pfizer Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Pfizer's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer (UKEX:PFE) Business Description

Industry
Address
66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer (UKEX:PFE) Headlines